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Time Interval Between Staging FDG Positron 
Emission Tomography (PET) and Initiation of 
Stereotactic Lung Radiotherapy (SBRT) Impacts 
the Risk of Recurrence and Metastasis in 
Non-small Cell Lung Cancer (NSCLC)
Background
To study influence of time interval from staging PET scanning to 
RT start time on recurrence and survival in patients with NSCLC 
undergoing lung SBRT.
Methods
Four-hundred eleven patients were treated with lung SBRT for 
T1-T2N0M0 NSCLC at 5 international institutions using online 
cone-beam CT (CBCT) image-guided radiotherapy (Elekta Oncology 
CBCT) from the period 1998 to 2009. Eight percent (8%) of patients 
had a synchronous primary tumor and 62% of tumors were biopsy-
proven. All patients were staged with a diagnostic CT scan; 84% also 
had FDG-PET and 5% had CT, PET and mediastinoscopy. Sixty-eight 
percent (68%) had T1N0 tumors, 30% T2N0 and 1% were locally 
recurrent after surgery. The median maximum tumor dimension 
was 2.4 cm (range 0.9-8.5cm). Patients were treated with a variety of 
prescription doses according to each institution’s protocol. The most 
common fractionation schedules were: 18-20Gy x 3; 12Gy x 4; 12Gy 
x 5; and 12.5Gy x 3 (median dose 54 Gy, 3 fractions). Mean follow-up 
time=1.3y.
Results
Median time from PET to SBRT was 5.7 weeks (wks) (0-30.4 
wks); median number of days elapsed during RT was 8d. Thirteen 
percent (13%) of patients underwent PET ≤ 2 wks of SBRT, while 
76% underwent PET ≤8.5 wks of SBRT. The median time from 
mediastinoscopy to SBRT was “x” wks (range). For all patients, 1y 
overall survival (OS) and cause specific survival (CSS) were 83% and 
94%, and at 2y 64% and 91%, respectively. Two years OS and CSS for 
patients who underwent PET staging were 62% and 87% compared to 
44% and 74% for those who did not (p=0.03, 0.04, respectively). There 
were no differences in local recurrence (LR) or regional recurrence 
(RR) for patients undergoing staging PET vs. no PET (p=NS); LR 
7% vs 8%, RR 9% vs 13%. However, DM was substantially higher in 
those without staging PET vs. those with staging PET (37% no PET 
vs. 22% PET, p=0.007), as was the risk of death (Hazard ratio 1.53 for 
no PET, p=0.03 Cox regression). Although the mere staging presence 
of PET did not impact the risk of RR, the time from staging PET to 
SBRT predicted both RR and DM, with a trend for predicting death 
on multivariate analysis (p=0.1). Patients undergoing PET ≤8.5 wks 
of SBRT had RR of 10% vs. 24% for a time interval >8.5 wks from 
PET to SBRT start. A time interval >8.5 wks from PET to SBRT start 
doubled the risk of DM from 18% to 37% (p=0.02). No statistically 
significant differences existed in any recurrence or survival endpoints 
for patients undergoing vs. not mediastinoscopy.
Conclusion
The use of staging PET prior to SBRT for NSCLC improved OS and 
CSS and substantially reduced DM and death. A time interval >8.5 
weeks between staging PET and initiation of SBRT increased the risk 
of RR and DM. The results of this analysis substantiate the importance 
of staging PET for NSCLC patients treated curatively with SBRT and 
emphasize the importance of timely staging for optimal outcomes. 
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